OAM
NBIX icon

Oxford Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Oxford Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,101
Closed -$298K – 664
2025
Q4 		$298K Buy
+2,101
New +$304K 0.11% 303
2025
Q2 		– Sell
-3,051
Closed -$337K – 678
2025
Q1 		$337K Buy
+3,051
New +$387K 0.15% 226
2024
Q4 		– Sell
-7,777
Closed -$896K – 553
2024
Q3 		$896K Buy
7,777
+4,578
+143% +$628K 0.75% 21
2024
Q2 		$440K Buy
+3,199
New +$439K 0.43% 64
2020
Q1 		– Sell
-39,120
Closed -$4.21M – 895
2019
Q4 		$4.21M Buy
39,120
+27,770
+245% +$2.91M 0.12% 189
2019
Q3 		$1.02M Buy
+11,350
New +$1.06M 0.02% 934
2018
Q4 		– Sell
-7,346
Closed -$892K – 1974
2018
Q3 		$892K Buy
+7,346
New +$833K 0.02% 1060
2018
Q2 		– Sell
-25,974
Closed -$2.15M – 1844
2018
Q1 		$2.15M Buy
25,974
+3,251
+14% +$275K 0.05% 533
2017
Q4 		$1.76M Buy
+22,723
New +$1.55M 0.04% 643
2017
Q2 		– Sell
-39,340
Closed -$1.7M – 1621
2017
Q1 		$1.7M Sell
39,340
-20,103
-34% -$861K 0.04% 568
2016
Q4 		$2.3M Buy
+59,443
New +$2.69M 0.08% 287
2013
Q4 		– Sell
-211,439
Closed -$2.39M – 760
2013
Q3 		$2.39M Buy
+211,439
New +$2.91M 0.05% 408

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oxford Asset Management's NBIX Position: Q1 2026 in Review

Oxford Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,101 shares — an estimated $298K sold.

Oxford Asset Management first reported a position in NBIX in Q3 2013 and held it in 12 quarters. The position peaked at $4.21M in Q4 2019. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Oxford Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Oxford Asset Management sold 2,101 Neurocrine Biosciences shares in Q1 2026, an estimated $298K.
  • Oxford Asset Management first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 12 quarters.
  • Oxford Asset Management's Neurocrine Biosciences position peaked at $4.21M in Q4 2019.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.